Skip to Main Content

Facing a huge debt, pricing pressures, and various missteps, the new Teva Pharmaceutical (TEVA) chief executive on Monday overhauled his management team and reorganized key business units in a Hail Mary bid to revive the beleaguered drug maker.

Underscoring the severity of the situation, those exiting at the end of next month include three key executives: R&D chief Michael Hayden; Rob Koremans, who headed the global specialty medicines group; and Dipankar Bhattacharjee, who ran the global generic drug business.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED